1. Cancers (Basel). 2018 Nov 16;10(11):452. doi: 10.3390/cancers10110452.

Externalized Keratin 8: A Target at the Interface of Microenvironment and 
Intracellular Signaling in Colorectal Cancer Cells.

Albaret MA(1)(2), Vermot-Desroches C(3), Paré A(4)(5)(6), Roca-Martinez JX(7), 
Malet L(8)(9), Esseily J(10), Gerossier L(11), Brière J(12), Pion N(13), Marcel 
V(14), Catez F(15), De Souza G(16)(17), Vuillermoz B(18), Doerflinger F(19), 
Lavocat E(20), Subiger O(21), Rousset C(22), Bresson C(23), Mandon E(24), 
Jawhari A(25), Falson P(26), Jasmin M(27), Coute Y(28), Mertani HC(29), 
Saintigny P(30)(31)(32), Diaz JJ(33).

Author information:
(1)Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, 
Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. 
marie.albaret@lyon.unicancer.fr.
(2)Department of Translational Research and Innovation, Centre Léon Bérard, 
69373 Lyon, France. marie.albaret@lyon.unicancer.fr.
(3)iDD Biotech Bâtiment Accinov 317 avenue Jean Jaurès, 69007 Lyon, France. 
vermotdesroches.claudine@gmail.com.
(4)Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, 
Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. 
arnopare@gmail.com.
(5)Department of Translational Research and Innovation, Centre Léon Bérard, 
69373 Lyon, France. arnopare@gmail.com.
(6)Service de Chirurgie Maxillo-Faciale, Centre Hospitalier Universitaire, 37170 
Tours, France. arnopare@gmail.com.
(7)Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, 
Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. 
jxroca@free.fr.
(8)Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, 
Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. 
Lucie.MALET@lyon.unicancer.fr.
(9)Department of Translational Research and Innovation, Centre Léon Bérard, 
69373 Lyon, France. Lucie.MALET@lyon.unicancer.fr.
(10)Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, 
Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. 
jad_esseily@yahoo.com.
(11)Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, 
Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. 
laetitia.gerossier@wanadoo.fr.
(12)Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, 
Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. 
briere.johan@gmail.com.
(13)Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, 
Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. 
Nathalie.PION@lyon.unicancer.fr.
(14)Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, 
Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. 
Virginie.MARCEL@lyon.unicancer.fr.
(15)Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, 
Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. 
frederic.catez@lyon.unicancer.fr.
(16)Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, 
Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. 
Genevieve.DESOUZA@lyon.unicancer.fr.
(17)Department of Translational Research and Innovation, Centre Léon Bérard, 
69373 Lyon, France. Genevieve.DESOUZA@lyon.unicancer.fr.
(18)iDD Biotech Bâtiment Accinov 317 avenue Jean Jaurès, 69007 Lyon, France. 
vuillermoz.boris@laposte.net.
(19)iDD Biotech Bâtiment Accinov 317 avenue Jean Jaurès, 69007 Lyon, France. 
franck.doerflinger@gmail.com.
(20)iDD Biotech Bâtiment Accinov 317 avenue Jean Jaurès, 69007 Lyon, France. 
emilie.lavocat@hotmail.fr.
(21)iDD Biotech Bâtiment Accinov 317 avenue Jean Jaurès, 69007 Lyon, France. 
Olivier_subiger@yahoo.fr.
(22)iDD Biotech Bâtiment Accinov 317 avenue Jean Jaurès, 69007 Lyon, France. 
carine.rousset@gmail.com.
(23)iDD Biotech Bâtiment Accinov 317 avenue Jean Jaurès, 69007 Lyon, France. 
corinnebresson@hotmail.fr.
(24)CALIXAR Functional Membrane Proteins For Life, 60 avenue Rockefeller, 69008 
Lyon, France. emandon@calixar.com.
(25)CALIXAR Functional Membrane Proteins For Life, 60 avenue Rockefeller, 69008 
Lyon, France. ajawhari@calixar.com.
(26)Laboratory of Molecular Microbiology and Structural Biochemistry, CNRS UMR 
5086, IBCP, 69367 Lyon, France. pierre.falson@ibcp.fr.
(27)Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, 
Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. 
MelissaMarie.JASMIN@lyon.unicancer.fr.
(28)Biosciences and Biotechnology Institute of Grenoble-Laboratoire Biologie à 
Grande Echelle (BIG-BGE) U1038 INSERM/CEA/UGA, Commissariat à l'Energie Atomique 
et aux Energies Alternatives (CEA) Grenoble, F-38054 Grenoble CEDEX 9, France. 
yohann.coute@cea.fr.
(29)Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, 
Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. 
hichem.mertani@lyon.unicancer.fr.
(30)Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, 
Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. 
Pierre.SAINTIGNY@lyon.unicancer.fr.
(31)Department of Translational Research and Innovation, Centre Léon Bérard, 
69373 Lyon, France. Pierre.SAINTIGNY@lyon.unicancer.fr.
(32)Department of Medical Oncology, Centre Léon Bérard, 69373 Lyon, France. 
Pierre.SAINTIGNY@lyon.unicancer.fr.
(33)Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, 
Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. 
jean-jacques.diaz@lyon.unicancer.fr.

Accumulating evidence supports the remarkable presence at the membrane surface 
of cancer cells of proteins, which are normally expressed in the intracellular 
compartment. Although these proteins, referred to as externalized proteins, 
represent a highly promising source of accessible and druggable targets for 
cancer therapy, the mechanisms via which they impact cancer biology remain 
largely unexplored. The aim of this study was to expose an externalized form of 
cytokeratin 8 (eK8) as a key player of colorectal tumorigenesis and characterize 
its mode of action. To achieve this, we generated a unique antagonist monoclonal 
antibody (D-A10 MAb) targeting an eight-amino-acid-long domain of eK8, which 
enabled us to ascertain the pro-tumoral activity of eK8 in both KRAS-mutant and 
wild-type colorectal cancers (CRC). We showed that this pro-tumoral activity 
involves a bidirectional eK8-dependent control of caspase-mediated apoptosis in 
vivo and of the plasminogen-induced invasion process in cellulo. Furthermore, we 
demonstrated that eK8 is anchored at the plasma membrane supporting this dual 
function. We, therefore, identified eK8 as an innovative therapeutic target in 
CRC and provided a unique MAb targeting eK8 that displays anti-neoplastic 
activities that could be useful to treat CRC, including those harboring KRAS 
mutations.

DOI: 10.3390/cancers10110452
PMCID: PMC6266717
PMID: 30453567

Conflict of interest statement: The authors declare no conflicts of interests.